ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 ...
Healio

‘Readily available biomarker’ can predict outcomes in multiple myeloma

Please provide your email address to receive an email when new articles are posted on . Lymphopenia at diagnosis or during follow-up can predict OS among patients with multiple myeloma. Researchers ...
ascopubs.org

Machine Learning to Predict Interim Response in Pediatric Classical Hodgkin Lymphoma Using Affordable Blood Tests

Changes in ferritin, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), albumin, total white cell count (TWC), absolute lymphocyte count (ALC), and absolute eosinophil count were ...
ascopubs.org

Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.

Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data. Risk of second primary hematological malignancy post CAR ...
EurekAlert!

A routine blood test could help predict who benefits most from CAR T-cell therapy

Measuring the lymphocytes — white blood cells that fight infection — in a patient’s blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...